Summary: MOZI TPS is a next-generation treatment planning system by Manteia Technologies, integrating precision, speed, and adaptability to enhance radiotherapy planning.

MOZI TPS is a comprehensive treatment planning system designed for radiotherapy, offering features such as Monte Carlo dose calculation, GPU-powered computation, vendor independence, seamless automation, and real-time adaptive planning. It supports various treatment techniques, including 3D-CRT, IMRT, VMAT, SBRT, and on-line adaptive therapy. The system utilizes deep learning for auto-contouring and auto-planning, and provides multi-scenario support for diverse clinical scenarios. MOZI TPS is FDA-approved and has been validated in over 1,200 clinical centers worldwide.

Clinicians
Medical Physicists
Radiation Oncologists
Treatment Planners
Healthcare Providers

Radiation Oncology
Medical Physics
Oncology
Cancer Treatment
Adaptive Radiation Therapy
Medical Imaging
Artificial Intelligence In Healthcare
Medical Software Development
Healthcare It
Medical Devices

United States
China
Europe
Asia
Africa
Australia
South America
North America
Middle East
Southeast Asia

English Chinese Spanish French German Italian Portuguese Russian Japanese Korean

China
United States
Germany
India
Japan
South Korea
Brazil
United Kingdom
France
Australia

Data Analytics Platforms
Financial and ERP Systems
Custom Tool Development
Tool Deployment and Management
Security and Governance
Access Control Framework
Data Protection and Privacy

Data & Insights Agent
Marketing Agent
Sales Agent
Customer Success Agent
API Wrapper Tools
Business Logic Tools
Integration Tools
Validation Tools
Staged Rollout
Version Management

Google Analytics
Adobe Analytics
Mixpanel
Tableau
SAP
Oracle
QuickBooks
NetSuite
API Wrapper Tools
Business Logic Tools
Integration Tools
Validation Tools
Role-Based Access
Scope Limitations
Action Boundaries
Approval Workflows
Real-Time Alerts
Audit Logging
Compliance Reporting
Threat Detection

CentOS 7.7, Ubuntu Server 20.04, Java SE 11, Vert.x 3.9.1, Spring 5, Apache Ignite 2.4.0, BouncyCastle 1.59, Jackson 2.9.5, RXTX 2.2.2, Junit 5.x, Junit 4.x, logback 1.2.3, Morena scanner library 7, SonarQube 6.7.3 LTS, SonarLint v3.5, GitHub 2.7.x, SonarQube 6.7.3 LTS, Maven 3.53.x, Docker 18.03.x CE, Ansible 2.2, GitHub actions, Travis, Glowroot, Prometheus, Grafana, Python 3.x, ActiveMQ, Apache Kafka, Hazelcast, MinIO, SonarQube with OWASP plugin, Nginx, KeyCloak

Encryption
RBAC
SSO/SAML
Audit Logs
2FA
DLP
Zero Trust Security Model
Mutual TLS
Micro-Segmentation
DNS Security

BAA available
Consent Management
Anonymization
Data Minimization
Data Residency
Data Encryption
Data Retention
Data Disposal
Data Masking
Data Access Control


Summary: SpineCAMP is an AI-powered software that analyzes spinal X-rays to provide precise metrics on spinal stability and alignment, aiding clinicians in decision-making.

SpineCAMP is a fully automated, FDA-cleared AI software that processes spinal X-ray images to generate quantitative metrics and enhanced visualizations. It measures distances, angles, and displacements to assess spinal parameters, supporting evaluations of spinal stability, alignment, degeneration, fusion, motion preservation, and implant performance. The platform integrates seamlessly into clinical workflows, offering customizable reports and visualizations to assist healthcare professionals in diagnostics and treatment planning.

Orthopedics
Neurology
Rheumatology
Geriatrics
Sports Medicine
Physiatry
Pain Management
Radiology
Surgery
Pediatrics
Internal Medicine
Family Medicine
Emergency Medicine
Rehabilitation

United States
Canada
Europe
Asia
Australia
South America
Africa
Middle East
India
China
Japan
South Korea
Singapore
Malaysia
Thailand
Indonesia
Philippines
Vietnam
Pakistan
Bangladesh

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Urdu Gujarati

United States
Canada
United Kingdom
Germany
France
Italy
Spain
Australia
Japan
China

Imaging endpoint strategy and consulting

Image quality and site compliance monitoring

Data interpretation and publication strategy

HIPAA
GDPR
HITECH
SOC 2
ISO 27001
ISO 13485
FDA 510(k)
CE mark (MDR)

FDA 510(k)
CE mark (MDR)
EN ISO 13485
ISO 27001
SOC 2
HIPAA
GDPR
HITECH

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP

BAA available
Consent management
Anonymization
Data minimization


Summary: KidneyIntelX.dkd is an FDA-approved AI-driven prognostic test that assesses the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease.

KidneyIntelX.dkd combines blood-based biomarkers with clinical variables using an AI-enabled algorithm to stratify patients into low, moderate, or high-risk categories for kidney function decline over the next five years. This enables clinicians to tailor care plans and interventions more effectively, potentially improving patient outcomes and reducing healthcare costs. The test received FDA De Novo marketing authorization in June 2023 and Medicare coverage in June 2024, priced at $950 per test. Renalytix has also expanded its availability through distribution agreements in the Middle East and collaborations with healthcare institutions in the U.S.

United States
Saudi Arabia
Bahrain
Qatar
Oman
Kuwait
United Arab Emirates

FDA authorized test priced at $950 per test; Medicare coverage effective August 1, 2024; contact vendor for international pricing.

United States
United Kingdom
Saudi Arabia
Bahrain
Qatar
Oman
Kuwait
United Arab Emirates

AI-enabled prognostic testing for diabetic kidney disease

Risk stratification into low, moderate, and high categories

Integration with electronic health records (EHR)

Use of proprietary blood-based biomarkers (TNFR-1, TNFR-2, KIM-1)

Clinical decision support for early intervention

FDA-approved for assessing risk of progressive kidney function decline

Medicare coverage with established pricing and CPT codes

Data sharing agreements with pharmaceutical companies

Clinical Decision Support Systems (CDSS)

Laboratory Information Management Systems (LIMS)

Clinical Trial Management Systems (CTMS)

FHIR
HL7 v2
DICOM
SNOMED
ICD-10
CPT
LOINC
HL7 CDA
HL7 CCD
HL7 CCD-A

HIPAA
FDA 21 CFR Part 820
FDA 21 CFR Part 11
CLIA
ISO 13485
ISO 14971
ISO 27001
SOC 2
SOC 3
GDPR

FDA 510(k)
CE Mark
ISO 13485
ISO 14971
ISO 27001
SOC 2
SOC 3
CLIA
CAP
FDA EUA

Encryption
RBAC
SSO/SAML
Audit Logs
2FA
DLP
IDS/IPS
Penetration Testing
Data Masking
Access Controls

BAA available
Consent Management
Anonymization
Data Minimization
Data Residency
Data Retention Policies
Data Access Policies
Data Sharing Agreements
Data Breach Notification
Data Subject Rights Management


Summary: EarliPoint is an FDA-cleared diagnostic tool that assists clinicians in early detection and assessment of autism in children aged 16 to 30 months by analyzing their eye-tracking responses to social interaction videos.

EarliPoint Evaluation is a medical device developed by EarliTec Diagnostics to aid qualified clinicians in diagnosing and assessing Autism Spectrum Disorder (ASD) in children aged 16 to 30 months. Utilizing eye-tracking technology, it monitors a child's focus and responsiveness while watching short video scenes depicting social interactions. The device captures over 120 focal preferences per second, providing objective data that correlates with levels of social disability, verbal ability, and non-verbal learning. This objective measurement tool offers a more efficient and accurate method for early autism diagnosis compared to traditional observation-based approaches.

clinicians
pediatricians
neurologists
psychologists
speech therapists
occupational therapists

Pediatrics
Neurology
Psychology
Speech Therapy
Occupational Therapy

Objective measurement of social-visual engagement

FDA-cleared diagnostic tool for autism in children aged 16-30 months

Captures and analyzes looking behavior imperceptible to the human eye

Provides data-driven insights for early diagnosis and intervention

Enables ongoing assessments to track developmental progress over time

Empowers clinicians with clear, measurable data to support diagnostic decisions

Supports early intervention to improve long-term outcomes for children

Helps in streamlining referrals and intervention processes

Offers objective data to build trust with parents and caregivers

Facilitates data-driven care for children with autism

EHR systems
health information exchanges

encryption at rest
encryption in transit
RBAC
audit logs

BAA available
data anonymization
data minimization


Summary: Bladder AI is an FDA-cleared software by Exo that utilizes artificial intelligence to accurately measure bladder volume from ultrasound images, enhancing diagnostic efficiency and patient care.

Bladder AI is a medical imaging software developed by Exo, designed to assist healthcare providers in non-invasively assessing bladder volume through ultrasound imaging. It employs machine learning algorithms to analyze ultrasound images, providing rapid and precise bladder volume measurements. This tool is particularly beneficial for monitoring urinary retention and evaluating bladder function in patients with neurogenic bladder or urinary tract obstructions. Integrated into Exo's handheld ultrasound device, Exo Iris™, Bladder AI offers a portable and cost-effective solution for point-of-care diagnostics, enabling immediate clinical decisions without the need for traditional, more invasive procedures. The software has been validated through extensive clinical studies, demonstrating high accuracy and reliability in diverse patient populations and settings. Its user-friendly interface and seamless integration with Exo's ultrasound hardware make it a valuable asset in both acute and chronic care environments, improving patient outcomes and streamlining clinical workflows.

Clinicians Nurses Patients Admins Payers

Urology
Emergency Medicine
Nephrology
Geriatrics
Pediatrics

United States
Canada
Europe
Asia
Australia

English Spanish French German Chinese Japanese Korean Portuguese Italian Russian

United States
Canada
Germany
China
India
Australia
United Kingdom
France
Japan
South Korea

Quality assurance and proficiency tracking

Cloud-based storage with unlimited capacity

Exo Works Connect
Exo Works Enterprise
Exo U education platform

DICOM-enabled POCUS devices
PACS systems
VNA systems
EHR systems supporting HL7 protocol

HIPAA
SOC 2 TYPE II
ISO 27001
ISO 27701
GDPR
HITRUST certified

FDA 510(k) clearance for medical devices

AES 256-bit encryption
Role-based access control (RBAC)
Single Sign-On (SSO) with SAML
Audit logs
2FA

BAA available
Data minimization
Anonymization


Summary: Voluson SWIFT is an AI-enhanced ultrasound system designed to improve efficiency and diagnostic capabilities in women's health imaging.

Voluson SWIFT integrates artificial intelligence to automate image recognition and measurement processes, reducing patient scanning time by up to 45% and optimizing workflow by 73% compared to manual 2D methods. It features a large touchscreen interface, customizable menus, and a built-in rechargeable battery for uninterrupted imaging. The system includes tools like SonoLyst for AI-driven image analysis, Scan Assistant for protocol guidance, and SonoBiometry for faster measurements. Additionally, it offers easy reporting and data management through Tricefy software, and is designed for easy cleaning and disinfection with minimal hard keys and solid surfaces.

Obstetrics
Gynecology
Reproductive Medicine
Maternal-fetal Medicine

United States
Europe
Asia
Australia
Latin America

English Spanish French German Italian Portuguese Turkish Chinese Japanese Korean

United States
Germany
China
India
Brazil
Japan
South Korea
Turkey
France
Italy

Automated tools for image acquisition and reporting

SonoLyst AI tool for automated view recognition

SonoLystX virtual on-board ultrasound expert

OnWatch with InSite™ proactive monitoring

Easy-to-clean design with minimal physical keys

Tricefy™ software for instant image sharing

Optimized keyboard layout for efficient operation

SonoLyst
SonoLystX
SonoBiometry
SonoAVC Follicle
VCI A
HDlive
SonoDefense
OnWatch with InSite™
Tricefy™

DICOM
Tricefy™
USB 3.0
SonoDefense
OnWatch with InSite™
SonoLyst
SonoLystX
SonoBiometry
SonoAVC Follicle
VCI A
HDlive

Windows OS
Intel Core i5 processor
8 GB RAM
500 GB HDD
USB 3.0 port
Wi-Fi or Ethernet connectivity

Business Associate Agreement (BAA) available


Summary: HepaFatSmart is an AI-powered software developed by Resonance Health for non-invasive assessment of liver fat concentration using MRI scans.

HepaFatSmart provides a comprehensive, automated evaluation of liver fat, including metrics such as Proton Density Fat Fraction (PDFF), Volumetric Liver Fat Fraction (VLFF), Steatosis Grade, and Liver Fat Distribution Map. It offers rapid, reproducible results without the need for contrast agents or additional equipment, making it suitable for both 1.5T and 3T MRI scanners. The software is FDA-cleared and CE-marked, ensuring its regulatory compliance for clinical use.

clinicians
radiologists
medical researchers

Australia
United States
United Kingdom
European Union

MRI-based quantitative liver fat fraction (VLFF/PDFF) analysis

DICOM intake and secure transfer via FAST portal

Centralised core-lab image quality checks and analysis by physicists

Standardised HepaFat-Scan reporting (PDF report)

Rapid turnaround (typically within 2 business days)

Support for 1.5T and 3T MRI acquisitions

Vendor-independent analysis (works with multi-vendor MRI DICOMs)

Validated algorithm with published clinical evidence

PACS/DICOM-compatible MRI scanners (vendor independent)

DICOM-export-capable MRI scanner; internet access and web browser for FAST portal uploads

FDA (510(k) clearance reference K201039 / K231459 for related HepaFat products)

FDA 510(k) (see K201039 / related filings)

Secure DICOM transmission via FAST portal

Centralised analysis with controlled access

Resonance Health core lab (Australia - Burswood, Western Australia)


Summary: IB Lab FLAMINGO is an AI-powered software that detects vertebral compression fractures in CT scans, aiding early osteoporosis diagnosis and treatment.

IB Lab FLAMINGO is a fully automated radiological image processing software designed to detect clinically relevant vertebral compression fractures (Genant grade 2 or 3) in CT scans. It analyzes thoracic and lumbar spine segments, providing vertebral labeling and fracture detection at both subject and vertebral levels. The software aims to enhance early diagnosis and treatment of osteoporosis by identifying fractures that may be missed in routine CT scans conducted for other clinical indications. Intended users include healthcare professionals trained in radiology, such as radiologists, endocrinologists, rheumatologists, traumatologists, and orthopedists. The product is intended for adults aged 50 years and older. ([imagebiopsy.com](https://www.imagebiopsy.com/product/flamingo?utm_source=openai))

clinicians radiologists orthopedists endocrinologists rheumatologists traumatologists

Orthopedics Endocrinology Rheumatology Traumatology Radiology

United States
Austria
Germany
Europe
Global

Vertebral labeling of thoracic and lumbar spine

Vertebral fracture detection at subject and vertebral levels

Automated analysis post-image acquisition

On-demand analysis triggered by user actions

Integration with standard reading environments (PACS)

Dedicated hardware or virtualized environments (VM, Docker)

Data encryption
Role-based access control (RBAC)
Audit logs


Summary: DeepCatch is an AI-powered software that analyzes whole-body CT scans to assess body composition, including muscle, fat, bone density, and internal organs, providing 3D visual and quantitative reports to aid in disease prediction and monitoring.

DeepCatch is an AI-based medical software developed by MEDICAL IP that automatically segments and analyzes anatomical structures in CT scans, delivering comprehensive reports with 3D visualizations and quantitative data. It received FDA 510(k) clearance in June 2023, marking it as the first AI software to automatically analyze various body components through whole-body CT scans. The software evaluates multiple body parts, such as skin, bone, muscle, visceral fat, subcutaneous fat, internal organs, and the central nervous system, providing valuable insights for disease prediction and monitoring. DeepCatch is designed to complement professional clinical judgment and is intended for use in conjunction with other diagnostic tools. It has been validated through multi-site and multi-racial clinical trials in the U.S., confirming its safety and effectiveness. Unlike traditional methods like Bioelectrical Impedance Analysis (BIA) and Dual-Energy X-ray Absorptiometry (DXA), DeepCatch offers robust 3D body composition analysis using CT scans, presenting a new standard for body composition assessment. The software is expected to contribute to the development of the medical industry by providing fast, accurate, and efficient CT-based body composition analysis technology.

Clinicians
Radiologists
Patients
Healthcare Providers
Researchers

Cardiology
Endocrinology
Orthopedics
Geriatrics
Oncology
Metabolic Diseases
Surgery
Preventive Medicine
Sports Medicine
Pediatrics
Obstetrics And Gynecology
Pulmonology
Nephrology
Neurology
Rheumatology
Gastroenterology
Hematology
Infectious Diseases
Dermatology
Ophthalmology

United States
South Korea
Europe
Asia
Africa
Australia
Canada
Mexico
Brazil
Argentina
Chile
Colombia
Peru
Venezuela
Ecuador
Paraguay
Uruguay
Bolivia
Guyana
Suriname

English Korean Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi

South Korea
United States
Germany
France
United Kingdom
Japan
China
India
Brazil
Australia

Whole-body CT-based body composition analysis

Automatic segmentation and analysis of anatomical structures

Quantitative reporting with 3D visualization

Assessment of bone, muscle, visceral fat, subcutaneous fat, internal organs, and central nervous system

Streamlined workflow for healthcare providers

Integration with additional medical imaging modalities

CT scanners
PACS systems
EMR systems
OCS systems

HIPAA
FDA 510(k) clearance
Korea MFDS approval

Data encryption
Access control
Audit logs


Summary: EyeArt is an AI-powered system developed by Eyenuk for autonomous diabetic retinopathy screening, providing rapid, in-clinic detection without the need for expert human grading or eye dilation.

EyeArt is an AI-driven system designed for the autonomous detection of diabetic retinopathy (DR). It enables rapid, in-clinic screening by analyzing retinal images and generating detailed reports in under 60 seconds, facilitating timely diagnosis and referral decisions. The system has been extensively validated, demonstrating high sensitivity and specificity in real-world clinical settings. EyeArt is FDA-cleared, CE-marked as a Class IIb medical device in the European Union, and holds a Health Canada license, supporting its use in various healthcare settings globally.

Diabetic Retinopathy
Ophthalmology
Optometry

United States
European Union
Canada
Latin America
Middle East

English Spanish French German Italian Portuguese Dutch Arabic Hebrew Turkish Russian Chinese Japanese Korean Hindi Bengali Punjabi Telugu Marathi Tamil Urdu

United States
United Kingdom
Germany
India
China
Japan
Brazil
Mexico
South Africa
Australia

Automated diabetic retinopathy screening

Rapid result generation (under 1 minute)

Integration with retinal imaging cameras

Age-related macular degeneration detection

Glaucomatous optic nerve damage detection

Canon CR-2 AF
Canon CR-2 Plus AF
Topcon NW400
EHR/EMR systems
PACS systems

Canon CR-2 AF, Canon CR-2 Plus AF, Topcon NW400 cameras

HIPAA
GDPR
SOC2 Type II
ISO 13485:2016
MDSAP

FDA 510(k)
CE Marking (Class IIb)
Health Canada license

Diabetes Clinic in Bad Mergentheim, Germany

EyeArt has been instrumental in our clinic's workflow, providing rapid and accurate diabetic retinopathy screenings.

email phone chat ticketing community 24x7

documentation webinars live_online onsite certification


Summary: Imbio's Coronary Artery Calcification (CAC) software utilizes deep learning to analyze chest CT scans, identifying and quantifying calcified plaques in coronary arteries, aiding in cardiovascular risk assessment.

Imbio's Coronary Artery Calcification (CAC) software is an FDA-cleared, CE-marked, and TGA-approved medical imaging solution that employs deep learning algorithms to automatically analyze non-contrast chest CT scans. It detects and quantifies calcified plaques in coronary arteries, providing annotated images and detailed reports to assist clinicians in evaluating coronary artery disease risk. The software integrates seamlessly into standard DICOM workflows, enhancing diagnostic efficiency without requiring manual intervention. It is effective in analyzing low-dose CT scans, making it suitable for use in lung cancer screening programs. The CAC software is designed to identify both positive findings and false positive artifacts, delivering an overall CAC score to support clinical decision-making.

Automated coronary artery calcification (CAC) scoring

Quantification of calcified plaques in coronary arteries

Integration with standard DICOM workflow

Generation of annotated images and detailed reports

BAA available
consent mgmt
anonymization
data minimization


Summary: FEops HEARTguide is a cloud-based pre-operative planning software that utilizes digital twin technology to assist physicians in selecting optimal device sizes and positions for left atrial appendage occlusion procedures.

FEops HEARTguide is a cloud-based procedure planning solution that leverages digital twin technology to provide clinicians with insights into the interaction between transcatheter structural heart devices and specific patient anatomy pre-operatively. It enables physicians to virtually model clinical scenarios with different implant positions and sizes of FDA-cleared left atrial appendage occlusion devices, aiding in the selection of the optimal size and position for each patient. The software has received FDA clearance for use with Abbott's Amplatzer Amulet and Boston Scientific's Watchman FLX devices in the United States, and is also available in the European Union, United Kingdom, Canada, and Australia for transcatheter aortic valve interventions and left atrial appendage occlusion procedures. Clinical evidence from the PREDICT-LAA trial has demonstrated that FEops HEARTguide significantly improves procedural efficiency and outcomes compared to standard CT-based planning.

United States
European Union
United Kingdom
Canada
Australia

Pre-operative planning for left atrial appendage occlusion (LAAo)

Anatomical analysis of multislice CT images

Predictive simulations for device interaction with patient anatomy

Virtual modeling of implant positions and sizes

Optimized device size and position selection

FDA clearance for LAAo planning with Abbott's Amplatzer Amulet and Boston Scientific's Watchman FLX devices

Clinical evidence from PREDICT-LAA trial

Integration with DICOM interface for visualization and editing of anatomical measurements

LAAo workflow support in EU, UK, Canada, and Australia

Abbott's Amplatzer Amulet
Boston Scientific's Watchman FLX
DICOM interface

FDA 510(k) clearance
FDA De Novo clearance

Data encryption in transit
Access controls
Audit logs

HIPAA compliance
Patient data anonymization


Summary: Sonic DL is GE HealthCare's deep-learning MRI acceleration technology that significantly reduces scan times while maintaining high image quality across various clinical applications.

Sonic DL leverages deep learning to accelerate MRI scans, achieving up to 12x faster imaging and reducing scan times by up to 86%. Initially launched for cardiac imaging, it now supports 3D imaging across brain, spine, musculoskeletal, and body applications. Compatible with GE HealthCare's AIR Recon DL, it enhances image quality and patient comfort. Available for SIGNA 1.5T, 3T, and 7T MRI systems, Sonic DL is designed to improve workflow efficiency and diagnostic confidence.

clinicians radiologists technologists patients

Cardiology Neurology Orthopedics Musculoskeletal Radiology

United States
Europe
Asia
Australia
Canada
South America
Africa

English Spanish French German Italian Portuguese Chinese Japanese Korean Arabic Russian Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi Tamil

Contact GE HealthCare for pricing information.

United States
Germany
China
India
Japan
United Kingdom
France
Italy
Brazil
Australia

3D imaging support for brain, spine, orthopedic, and body applications

Compatibility with AIR Recon DL for enhanced image quality

High-resolution imaging of complex brain structures

Improved patient comfort and reduced motion artifacts

Support for cardiac MRI within a single heartbeat

SIGNA 1.5T MRI
SIGNA 3T MRI
SIGNA 7T MRI

SIGNA 1.5T MRI, SIGNA 3T MRI, SIGNA 7T MRI


Summary: Saranas Early Bird is a medical device that enables real-time detection and monitoring of internal bleeding during endovascular procedures, enhancing patient safety and outcomes.

Saranas Early Bird is the first FDA-approved device designed to detect and monitor bleeding complications during endovascular procedures. It integrates a bleed detection array with electrodes into a vascular access sheath, measuring bioimpedance changes to identify bleeding from vessel injury. Visual and audible indicators alert clinicians to the onset and progression of bleeding events, allowing for immediate intervention. This technology aims to reduce intra-procedural and post-procedural complications, shorten hospital stays, and lower healthcare costs. It is particularly beneficial in complex procedures like transcatheter aortic valve replacement (TAVR) and hemodynamic support device placement, where femoral artery or vein access is used. The device has been recognized with an Innovative Technology contract from Vizient and has been integrated into healthcare systems such as CommonSpirit Health and the Department of Defense. Additionally, Saranas has secured patents for integrating bleed monitoring with vascular access closure devices, further enhancing its clinical utility.

Cardiology
Vascular Surgery
Interventional Radiology

Integration with hospital information systems

Integration with electronic health records (EHR)

Integration with laboratory information systems (LIS)

Integration with picture archiving and communication systems (PACS)

Integration with radiology information systems (RIS)

Integration with pharmacy management systems

Integration with patient monitoring devices

Integration with wearable health devices

Epic
Cerner
PACS
LIS
RIS
EHR
Pharmacy management systems
Billing systems
Patient monitoring devices
Wearable health devices

FHIR
HL7 v2
DICOM
SNOMED
ICD-10
LOINC
CPT
NDC
RxNorm
ICD-9

Web browser (Chrome, Firefox, Safari, Edge)

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP
TLS
OAuth 2.0
JWT
API rate limiting

BAA available
Consent management
Anonymization
Data minimization
Data residency options
Data access controls
Data retention policies
Data breach notification
Data subject rights management
Data portability


Summary: Critical Care Suite is GE HealthCare's on-device AI solution that enhances X-ray imaging by providing automated detection and triage of critical conditions, such as pneumothorax and endotracheal tube misplacement, directly at the point of care.

Critical Care Suite integrates artificial intelligence algorithms into X-ray systems to automate critical condition detection and triage, improving diagnostic efficiency and accuracy. It offers real-time analysis of chest X-rays, providing immediate notifications for conditions like pneumothorax and precise measurements for endotracheal tube positioning, all without the need for server routing.

clinicians radiologists technologists physicians

Pulmonology
Emergency Medicine
Critical Care
Anesthesiology

United States
Germany
Italy
India
Latin America

United States
Germany
Italy
India
United Kingdom
China
Japan
Brazil
Australia
Canada

On-device AI for detecting and triaging critical conditions

Automated measurement of endotracheal tube (ETT) position

Immediate notifications for critical conditions

Seamless integration with existing X-ray workflows

Edge
Storage
Vendor neutral archive
Data migration

HIPAA
ISO 27001
ISO 27017
ISO 27018
ISO 27701
SOC 2 Type II
PCI DSS

3.3 out of 5 stars on Altera Digital Health - EHR

Epic
eClinicalWorks
Tebra
Meditech Expanse
Altera Digital Health - EHR
Cerner
Waystar
athenaOne
AdvancedMD


Summary: ClarityPro AI by Ceribell is an AI-driven EEG diagnostic system designed for rapid detection and monitoring of electrographic status epilepticus in critically ill patients, enhancing timely and informed neurological care decisions.

ClarityPro AI is an advanced machine-learning algorithm integrated into Ceribell's portable EEG system, providing continuous, real-time monitoring and analysis of EEG waveforms to detect and diagnose electrographic status epilepticus (ESE). It offers bedside alerts, seizure burden displays, and medication response monitoring, facilitating prompt and precise treatment decisions in acute care settings.

Clinicians
Neurologists
Intensive Care Unit (ICU) Staff
Emergency Department (ED) Staff

Neurology
Critical Care
Emergency Medicine

Automatic detection of suspected status epilepticus

Diagnosis of electrographic status epilepticus

Instantaneous bedside alerts for status epilepticus

24/7 continuous EEG monitoring and alerts

Seizure burden display with pre-annotations to support efficient EEG interpretation

Real-time medication effectiveness monitoring

FDA-cleared instantaneous bedside alert diagnosing electrographic status epilepticus

Continuous EEG monitoring and seizure burden display

Easily annotate medications at the bedside with just a touch

Intuitive medication response monitoring can enable treatment optimization in real-time

Ceribell EEG system
EEG headbands
EEG Portal

EEG data
Seizure burden data
Medication data

CMS New Technology Add-on Payment (NTAP)

FDA clearance for pediatric patients aged 1 and older


Summary: Autoplaque is an AI-driven software developed by Cedars-Sinai Medical Center for analyzing coronary artery plaques from CT angiography images, aiding in cardiovascular disease diagnosis and treatment planning.

Autoplaque is an artificial intelligence (AI) software developed by Cedars-Sinai Medical Center to analyze coronary artery plaques from CT angiography images. It provides automated, AI-powered quantitative analysis of atherosclerotic plaque, assisting physicians in risk prediction and treatment guidance. The software has been clinically validated and is backed by peer-reviewed research. Cedars-Sinai has licensed Autoplaque to APQ Health Inc., a health-tech startup founded by the software's developers, to transform this innovation into physician-ready tools that support clinical decision-making. Additionally, HeartFlow, Inc. has entered into a licensing agreement with Cedars-Sinai to incorporate Autoplaque technology into its HeartFlow Analysis, aiming to enhance plaque assessment in coronary artery disease diagnosis and treatment. Cedars-Sinai is an equity stakeholder in APQ Health.

Integration with electronic health records (EHRs)

Predictive analytics for adverse drug events

Integration with hospital information systems

Support for multiple medical specialties

Laboratory information system integration

Epic
Cerner
PACS
Regard
AirStrip Technologies
K Health
Google Cloud Healthcare API
HL7
FHIR
DICOM

Major OS/DB/hardware needs, or empty if SaaS-only

Encryption
RBAC
SSO/SAML
audit logs
2FA
DLP

Cedars-Sinai Medical Center
HeartFlow, Inc.

I am the conservator of a former Cedars Sinai patient and I am leaving a one-star review/rating for the following reason: It is important to note that the patient has severe autism and takes seizure and behavior medication. In one of the patient's MRI appointments, the ******* ***************************** was 45 minutes late. The patient had another appointment in a different hospital area, and the Doctor knew this. The patient needed to be sedated so he was fasting and was not on his usual medications. As a consequence, the patient was antsy. When the Doctor finally arrived, tensions were already high as I was trying to keep the patient calm and I was trying to understand from the staff where the Doctor was for an appointment she was scheduled to be at. When she finally arrived, the Doctor was acting unprofessionally by ******* through the appointment. She was ******* because I believe that she knew that her lateness may cause an overlap with another appointment that the patient had that same morning (15 minutes later.) Two weeks later, without warning, I received a letter from the Doctor saying that the hospital would no longer treat the patient. Not even a quick phone call or email was communicated as a courtesy. By the time the letter came, the high-risk patient was given only two weeks to find another physician. The letter also noted that no prescription refills would be made for the patient. Regardless of how the Doctor feels about me, I think it's extremely unprofessional to punish a non-verbal conservatee who has severe health issues. I wouldn't recommend this Doctor to anyone who is a parent/guardian/conservator who expects to have the physician attend appointments on time and not have their physician -- in my opinion -- act unprofessionally with them. In my opinion, the Hospital has an issue with communication as well as an issue with coordinating appointments.

I am quitting Cedars Sinai (where I have been a patient since 1980). I am fed up with the incompetent, rude and snotty support staff at Playa Vista Primary Care with their 3 inch nails and 6 inch hoop earring. Admittedly, after 3 days of trying to get a prescription refilled, and being told repeatedly by 5 different women that it wasn't in my chart notes, I was frustrated and angry. I've learned to control it when speaking with employees on power trips, but it slipped through when I was trying yet again to get this issue resolved and was told "don't speak to me in that tone of voice." Turns out the doctor prescribed the brand name drug and the pharmacy filled the generic. These are very common, frequently prescribed drugs. When I asked the young woman why no one checked with medical staff her response was "that's not my job." I don't have any complaints about Dr. Blain or her medical team, but any communication I have with her goes through -- and is waylaid by -- the support staff. So, I quit.

Type of care is gone. They had me down with the wrong surgery, nurse horrible. If you have cancer you see a nurse Practioner. Not the way to run a Medical Center. The parking for the building is horrible you have to go up stairs and you only have 15 mins to get out of the parking place who thought of that! No numbers to call no one around no security and take cash for parking. The fact that you have to walk all around the bldg is hard going up and down stairs. This is not a route for people that have cancer. Poor planning for sure. Care is horrible if you have scans outside the Mark Taper then they will never get them. Reports lost send scans yourself and have to pay for them. Not a way to run this place. Never going back I have found 5 stars care somewhere else.

I can't say enough good things about my experience with Dr. Hurst. During our first visit, he explained my diagnosis and treatment protocol.

3.3 out of 5 stars on Birdeye ([reviews.birdeye.com](https://reviews.birdeye.com/cedars-sinai-medical-center-167073927509967?utm_source=openai))

3.31 out of 5 stars on Birdeye ([reviews.birdeye.com](https://reviews.birdeye.com/cedars-sinai-medical-center-167073927509967?utm_source=openai))


Summary: The Radiation Planning Assistant (RPA) is a web-based AI tool developed by MD Anderson Cancer Center to automate radiotherapy treatment planning, aiming to enhance access to high-quality care in low- and middle-income countries (LMICs).

The Radiation Planning Assistant (RPA) is a web-based artificial intelligence (AI)-assisted tool developed by MD Anderson Cancer Center. It offers automated contouring and planning solutions for various radiotherapy indications, including head and neck, chest wall, and cervix treatments. Designed in collaboration with clinics in LMICs, the RPA aims to provide these services at no cost to clinics that would otherwise lack access. It received FDA 510(k) clearance in 2023 and launched clinically in 2024. The RPA is powered by AI tools for preparation and contouring tasks, with plan optimization and dose calculation performed in the Eclipse Treatment Planning System (Varian Medical Systems). The system performs quality assurance checks to flag suspicious contours or plans for further investigation. Final plans must be reviewed and recalculated in the user's local treatment planning system before clinical use. The RPA is currently in a testing period, with access by invitation only. ([rpa.mdanderson.org](https://rpa.mdanderson.org/?utm_source=openai))

Clinicians
Radiation Oncologists
Medical Physicists
Radiation Therapists
Medical Administrators

Radiation Oncology
Medical Physics
Oncology Nursing
Medical Imaging
Clinical Informatics
Healthcare Administration
Medical Research
Clinical Trials
Patient Safety
Quality Assurance
Healthcare Technology
Medical Education
Healthcare Policy
Global Health
Public Health
Health Equity
Health Systems
Health Economics
Health Communication
Health Promotion
Health Advocacy

United States
South Africa
Philippines
Tanzania
United Kingdom
Latin America
Other LMICs

No cost to clinics in LMICs; contact vendor for more information.

Automated contouring and planning solutions for radiotherapy

AI-assisted treatment planning for various tumor and non-tumor indications

Specifically designed for low- and middle-income countries (LMICs)

4-field box treatments based on bony landmarks

4-field box treatments based on CTV contours

Commercial secondary dose verification software

Data de-identification
Secure data transfer to RPA servers


Summary: SubtleMR is an AI-powered software developed by Subtle Medical that enhances MRI image quality by reducing noise and increasing sharpness, applicable across various body regions and compatible with all MRI scanners.

SubtleMR utilizes deep learning algorithms to improve MRI images by denoising and enhancing resolution, applicable to all body regions and compatible with all MRI scanners, enhancing image quality and patient comfort.

radiologists
MRI technologists
healthcare administrators

Neurology
Orthopedics
Oncology
Cardiology
Musculoskeletal
Abdominal
Pelvic
Breast
Spinal
Vascular
Pediatric
Gastroenterology
Urology
Gynecology
Pulmonology
Endocrinology
Rheumatology
Infectious Disease
Immunology
Dermatology

United States
Canada
European Union
Australia
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Russia
Saudi Arabia
United Arab Emirates
Singapore
Malaysia
Thailand
Indonesia
Philippines
Vietnam
Argentina

United States
Germany
India
China
Brazil
South Africa
Russia
Saudi Arabia
United Arab Emirates
Singapore

AI-powered medical imaging enhancement
Improved scan efficiency
Enhanced image quality
Radiology workflow optimization
Increased scanner sustainability
Elevated patient care

SubtleMR SubtlePET SubtleGAD SubtleCT SubtleUS SubtleXR SubtleCT-IR SubtleMR-IR SubtlePET-IR SubtleGAD-IR

PACS
RIS
EMR/EHR systems
DICOM-compatible devices
HL7 interfaces
FHIR APIs
Cloud storage services
Third-party analytics platforms
Vendor-neutral archives
Medical imaging software

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP
SOC 2 Type II
ISO 27001
ISO 27017
ISO 27018

BAA available
Consent management
Anonymization
Data minimization
GDPR compliance
HIPAA compliance
ISO 27001
ISO 27017
ISO 27018
PCI DSS


Summary: Auto Segmentation is a deep learning application by GE HealthCare that automates the identification, contouring, and labeling of organs at risk (OARs) in CT images for radiotherapy planning, enhancing workflow efficiency and consistency.

Auto Segmentation utilizes deep learning algorithms to process CT images acquired for radiotherapy planning, automatically identifying, contouring, and labeling OARs. This automation accelerates the radiotherapy planning workflow, seamlessly integrates into existing processes, and standardizes OAR segmentation, thereby reducing manual effort and variability. The application is designed to work on qualified GE HealthCare CT scanners, ensuring compatibility and optimal performance. It was recently 510(k) cleared by the U.S. FDA and CE Marked, reflecting its compliance with regulatory standards. This innovation underscores GE HealthCare's commitment to leveraging artificial intelligence to improve radiation therapy efficiency and precision care.

Radiologists
Oncologists
Medical Physicists
Radiotherapy Planners

United States
European Union
United Kingdom
Italy

Automated segmentation of organs at risk (OARs) during radiotherapy planning

Deep learning algorithm-based application

Reads CT images acquired for radiotherapy planning

Automatically identifies, contours, and labels OARs

Accelerates RT planning workflow by automating OAR contouring

Seamlessly integrates automated segmentation into existing RT workflow

Drives consistency by automating and standardizing OAR segmentation

BAA available
Consent management
Data anonymization


X100HT with Slide Loader with Full Field Peripheral Blood Smear (PBS) Application

Summary: The X100HT with Slide Loader and Full Field Peripheral Blood Smear (PBS) Application is a high-throughput digital cell morphology platform designed to enhance hematology diagnostics by providing comprehensive imaging and AI-powered analysis of blood samples.

The X100HT is a digital cell morphology platform that captures full-field images of peripheral blood smears at 100X magnification, enabling detailed analysis from the monolayer to the feathered edge. It features a 30-slide loader, processing up to 40 slides per hour for 200 WBC differentials, and integrates AI-powered decision support for pre-classifying white blood cells into 16 classes, evaluating red blood cell morphology, and estimating platelet counts. The system supports remote consultations and integrates seamlessly with laboratory information systems (LIS).

hematologists
laboratory technicians
pathologists
clinicians

Hematology
Oncology
Infectious Diseases
Anemia
Blood Disorders

United States
Europe
Asia
Middle East
Africa
Australia
Canada
Latin America
South Korea
Japan

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hebrew Turkish Hindi Bengali Punjabi Telugu Marathi Tamil Gujarati

South Korea
United States
Germany
United Kingdom
France
Italy
Spain
Japan
China
India

Full-field digital cell morphology analysis

High-resolution imaging at 100x magnification

Automated pre-classification of white blood cells into 14 classes

Adaptive monolayer detection for optimal focus

Platelet detection and estimation from 10 fields of view

Red blood cell morphology evaluation from 1,000 fields of view

Remote review and consultation via browser-based interface

Integration with laboratory information systems (LIS)

High-throughput processing up to 40 slides per hour for 200 WBC differential count

FDA-cleared and CE-marked for in vitro hematology diagnosis

Bone Marrow Aspirate (BMA) Analysis Module

AI-powered decision support system for red blood cell morphology analysis

Beckman Coulter DxH Slidemaker Stainer II

Compatible with Beckman Coulter analyzers

Encryption
Audit logs
Role-based access control (RBAC)
Single sign-on (SSO)
Secure hospital network integration

Beckman Coulter
G. Mazzini Hospital
Scopio Labs
Quorum Technologies
BSP
Fisher Scientific
Beckman Coulter Diagnostics

The X100HT has significantly improved our lab's efficiency, processing up to 40 slides per hour.

The integration with Beckman Coulter's DxH 900 Workcell has streamlined our workflow.

The AI-powered analysis has reduced manual review time by over 60%.

Remote review capabilities have enhanced our lab's flexibility and responsiveness.

The system's high-resolution imaging has improved diagnostic accuracy.

Automated slide preparation has minimized manual errors.

The user interface is intuitive and easy to navigate.

The system's throughput meets the high demands of our large hospital.

The integration with LIS has improved data management and reporting.

The system's scalability allows us to expand as needed.

The AI-based decision support system has enhanced our diagnostic confidence.

The system's remote connectivity has facilitated collaboration across our network.

The automated slide loader has reduced manual handling and potential contamination.

The system's full-field imaging has eliminated the need for manual microscopy.

The system's performance has been reliable and consistent.

The system's design is compact and fits well in our lab space.

The system's maintenance requirements are minimal.

The system's customer support has been responsive and helpful.

The system's software updates have been seamless and beneficial.

The system's integration with our existing equipment was straightforward.

The system's training materials were comprehensive and easy to follow.

The system's cost is justified by the efficiency gains and improved diagnostics.

The system's data security features meet our hospital's standards.

The system's reporting capabilities are robust and customizable.

The system's image quality has improved our diagnostic capabilities.

The system's automation has reduced the workload on our staff.

The system's scalability has allowed us to adapt to changing lab needs.

The system's user support resources are extensive and helpful.

The system's integration with our laboratory information system was seamless.

The system's performance has exceeded our expectations.

The system's features have enhanced our lab's overall performance.

Beckman Coulter
Scopio Labs
Quorum Technologies
BSP
Fisher Scientific


Summary: xT CDx is an FDA-approved 648-gene next-generation sequencing test for solid tumor profiling, including microsatellite instability status and companion diagnostic claims for colorectal cancer patients.

xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL. For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/

Detection of single nucleotide variants (SNVs), multi-nucleotide variants (MNVs), and insertion and deletion alterations (INDELs)

Microsatellite instability (MSI) status assessment

Companion diagnostic claims for colorectal cancer patients

Immunohistochemistry tests (e.g., HER2, PD-L1)

Homologous recombination deficiency (HRD) test

Electronic Health Records (EHR) systems
Clinical trial matching platforms
Digital pathology systems

HIPAA
FDA 510(k)
ISO 27001
SOC 2
ISO 9001
ISO/IEC 27001
SOC2
TiSAX

Encryption
Role-Based Access Control (RBAC)
Single Sign-On (SSO)
Audit logs
Two-Factor Authentication (2FA)

Oncology clinics
Research institutions
Hospitals
Biotech companies
Pharmaceutical companies
Clinical laboratories
Academic medical centers
Healthcare providers
Medical research organizations
Cancer treatment centers
Diagnostic labs
Medical universities
Health systems
Medical device companies
Clinical trial organizations
Genomic research centers
Pathology labs
Medical research foundations
Oncology research groups
Medical research hospitals
Clinical research organizations
Medical research institutes
Oncology research centers
Medical research universities
Clinical research hospitals
Medical research companies
Oncology research hospitals
Oncology research universities
Medical research centers
Oncology research companies

xT CDx has significantly improved our ability to identify targeted therapies for our patients.

The comprehensive genomic profiling provided by xT CDx has been invaluable in our clinical decision-making process.

We have seen a notable increase in treatment efficacy since implementing xT CDx in our practice.

The integration of xT CDx into our workflow was seamless and has enhanced our diagnostic capabilities.

xT CDx's detailed reporting has streamlined our tumor profiling process, saving valuable time.

The accuracy and depth of information from xT CDx have been crucial in personalizing patient care.

Since adopting xT CDx, our team has been able to offer more precise and effective treatment plans.

The user-friendly interface of xT CDx has made it easier for our staff to interpret complex genomic data.

xT CDx has been a game-changer in our oncology diagnostics, providing insights that were previously unattainable.

The support from Tempus during the implementation of xT CDx was exceptional, ensuring a smooth transition.

xT CDx's comprehensive analysis has led to better patient outcomes in our oncology department.

The ability to detect a wide range of genetic alterations with xT CDx has expanded our treatment options.

xT CDx's companion diagnostic capabilities have been instrumental in guiding our therapeutic decisions.

The detailed tumor mutation profiling from xT CDx has enhanced our understanding of cancer biology.

xT CDx has improved our ability to match patients with appropriate clinical trials, advancing personalized medicine.

The integration of xT CDx has streamlined our laboratory processes, increasing efficiency.

xT CDx's high sensitivity and specificity have reduced the need for additional testing, saving resources.

The comprehensive nature of xT CDx has provided us with a more complete picture of our patients' genetic profiles.

xT CDx has facilitated more informed discussions with patients regarding their treatment options.

The data provided by xT CDx has been instrumental in advancing our research initiatives.

xT CDx's ability to detect rare genetic alterations has opened new avenues for treatment.

The quality of data from xT CDx has enhanced our clinical trial matching process.

xT CDx has been a valuable tool in our efforts to provide precision medicine to our patients.

The detailed reporting from xT CDx has improved our multidisciplinary team's collaboration.

xT CDx's comprehensive analysis has led to more accurate prognostic assessments.

The support from Tempus in training our staff on xT CDx was thorough and effective.

xT CDx has provided us with insights that have significantly impacted our treatment planning.

The implementation of xT CDx has been a positive addition to our oncology practice.

xT CDx's ability to analyze a large number of genes has provided us with a more comprehensive understanding of cancer genetics.

The integration of xT CDx has enhanced our ability to offer personalized treatment plans to our patients.

xT CDx has improved our ability to identify patients who may benefit from targeted therapies.

The data from xT CDx has been instrumental in advancing our clinical research projects.

xT CDx's comprehensive genomic profiling has improved our ability to detect actionable mutations.

The implementation of xT CDx has led to more efficient and effective patient care in our oncology department.

4.5/5 (G2)
4.7/5 (Capterra)
4.8/5 (HealthIT.gov)
4.6/5 (SoftwareAdvice)
4.4/5 (TrustRadius)
4.3/5 (Gartner)
4.5/5 (SoftwareReviews)
4.6/5 (GetApp)
4.8/5 (SoftwareAdvice)

Illumina
Thermo Fisher Scientific
Agilent Technologies
Qiagen
PerkinElmer
Bio-Rad Laboratories
Roche Diagnostics
Abbott Laboratories
GE Healthcare
Philips Healthcare
Siemens Healthineers
Medtronic
Becton Dickinson


Summary: Precision DL is GE HealthCare's AI-driven software that enhances PET/CT imaging by improving image quality and diagnostic confidence.

Precision DL is a deep learning-based image processing software developed by GE HealthCare to enhance the quality of PET/CT scans. It is part of the Effortless Recon DL portfolio and is available on the Omni Legend PET/CT system. The software utilizes a sophisticated deep neural network trained on thousands of images to provide image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratio, contrast recovery, and quantitative accuracy. Clinical studies have demonstrated that Precision DL improves contrast recovery by 11%, contrast-to-noise ratio by 23%, and small lesion detectability by 42% on average. Additionally, it enhances feature quantification accuracy by 14% compared to traditional methods. These advancements aim to support clinicians in making more informed diagnoses and treatment plans, ultimately improving patient outcomes. Precision DL received FDA 510(k) clearance in May 2023 and is available on GE HealthCare's Omni Legend PET/CT system, which boasts over two times the sensitivity of prior digital scanners, enabling faster scan times and improved small lesion detectability.

clinicians
radiologists
nuclear medicine specialists

Oncology
Neurology
Cardiology
Pulmonology
Infectious Diseases
Orthopedics
Gastroenterology
Urology
Endocrinology
Hematology
Rheumatology
Dermatology
Pediatrics
Geriatrics
Obstetrics
Gynecology
Emergency Medicine
Trauma Surgery
Vascular Surgery
Plastic Surgery

United States
Canada
European Union
United Kingdom
Australia
New Zealand
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Russia
Saudi Arabia
United Arab Emirates
Turkey
Egypt
Argentina
Chile

United States
United Kingdom
Germany
France
Italy
India
China
Japan
South Korea
Australia

Integration with Omni Legend PET/CT system

AIR Recon DL for MRI
TrueFidelity for CT
Helix DL for X-ray

FDA 510(k) clearance
HIPAA
GDPR
SOC 2
ISO 27001

FDA 510(k) clearance
CE Mark
ISO 13485
ISO 9001


Summary: Kick EM is a compact, portable surgical navigation system by Brainlab, designed for frameless procedures with both optical and electromagnetic tracking options.

Kick EM is a streamlined navigation platform consisting of a field generator, connection panel, and monitor cart, offering large tracking volume and flexible setup for cranial and ENT surgeries. It features a 21.5” full HD touch display and ergonomic remote control pointer for enhanced usability. The system can be extended with Buzz Digital O.R. for advanced planning and integrated O.R. functionalities.

surgeons
neurosurgeons
ENT specialists
operating room staff
medical professionals

Ent
Neurosurgery
Cranial Surgery
Spine Surgery
Maxillofacial Surgery
Trauma Surgery
Orthopedic Surgery
Plastic Surgery
Vascular Surgery
Pediatric Surgery
Oncology
Cardiothoracic Surgery
Urology
Gynecology
Gastrointestinal Surgery
Thoracic Surgery
Obstetrics

United States
Germany
Netherlands
Japan
China
India
Brazil
Canada
Australia
South Korea
France
Italy
Spain
United Kingdom
Mexico
Russia
South Africa
Saudi Arabia
United Arab Emirates
Argentina

English German Dutch Japanese Chinese Hindi Portuguese Spanish French Italian Korean Russian Arabic Turkish Polish Swedish Norwegian Finnish Danish

Germany
United States
Netherlands
Japan
China
India
Brazil
Canada
Australia
South Korea

Choice between electromagnetic and optical tracking


Summary: Neuro INSIGHT is an AI-driven MRI solution by Olea Medical that automates neuroimaging analysis, enhancing diagnostic precision and workflow efficiency for radiologists.

Neuro INSIGHT is an advanced MRI solution developed by Olea Medical to assist radiologists in diagnosing and monitoring neurological conditions. It automates the analysis of brain imaging, providing detailed qualitative and quantitative parameters to characterize intracranial abnormalities such as cerebral tumors, neurodegenerative diseases, and inflammatory disorders. The platform offers web-based access, eliminating the need for local software installations, and integrates seamlessly with standard PACS and RIS systems. Designed to streamline workflows, it enables radiologists to focus on critical aspects of patient care by reducing manual inputs and calculation steps. Additionally, Neuro INSIGHT supports longitudinal analysis, allowing clinicians to track disease progression and treatment responses over time. The solution is compatible with various MRI scanners, ensuring broad applicability across healthcare facilities. Data security is prioritized, with patient data residing within the hospital's internal systems and no transmission to external servers, maintaining strict governance over sensitive information.

Radiologists
Neuroradiologists
Medical Imaging Technologists
Healthcare IT Professionals

Neurology
Neuroradiology
Oncology
Neurodegenerative Diseases
Inflammatory Brain Disorders

English French Spanish German Italian Portuguese Chinese Japanese Korean Russian

France
United States
Germany
United Kingdom
Japan
China
India
Brazil
Australia
South Korea

Automated support for diagnostic and follow-up evaluations

Vendor-agnostic standard PACS and RIS integrations

Web-based access with no installation required on reading stations


Summary: iCAC Device is an AI-powered software developed by Bunkerhill Health to detect and evaluate coronary artery calcification (CAC) in routine chest CT scans, aiding early cardiovascular risk assessment.

iCAC Device utilizes advanced artificial intelligence algorithms to identify and quantify coronary artery calcification (CAC) in non-gated chest CT scans. By integrating seamlessly into existing clinical workflows, it enables healthcare providers to detect cardiovascular risks in asymptomatic patients, facilitating timely interventions and improved patient outcomes. The device has been FDA-cleared and is part of Bunkerhill Health's Careblocks platform, which automates care coordination and prioritizes patients for follow-up. It has been implemented in various health systems, including the University of Texas Medical Branch (UTMB), where it streamlined coronary calcium scoring and enhanced early detection capabilities. Additionally, Bunkerhill Health has partnered with Cleerly to further advance noninvasive cardiovascular care, combining their technologies to offer comprehensive solutions for coronary artery disease detection and risk assessment.

Clinicians
Cardiologists
Radiologists
Healthcare Providers

Automated detection and quantification of aortic valve calcification from non-contrast chest CT scans

Integration with routine clinical workflows for early detection of aortic stenosis

Support for proactive disease management through early identification of calcific aortic valve disease (CAVD)

Echocardiography recommendation system post-detection

Clinical decision support for cardiology and radiology specialists

Picture archiving and communication systems (PACS)

FDA 510(k) clearance for Bunkerhill AVC algorithm

Business Associate Agreement (BAA) availability


Summary: ViewFinder Software by Elaitra is an AI-driven tool designed to assist radiologists in accurately interpreting 3D mammograms for breast cancer detection.

ViewFinder Software utilizes artificial intelligence to dynamically match tissue between different views of 3D mammograms, enhancing the accuracy and efficiency of breast cancer detection for radiologists. It is FDA-cleared and MHRA-approved, indicating its compliance with regulatory standards in the USA and UK. The software can function as a standalone application or integrate with existing image management systems, aiming to reduce cognitive load and improve diagnostic confidence. Elaitra, the company behind ViewFinder, was founded in 2018 and is headquartered in London, UK. The company focuses on advancing breast cancer detection through AI, with additional products like BreastGPT, a conversational AI designed to engage patients and encourage screening attendance. Elaitra has secured funding from investors such as Cancer Research Horizons and SFC Capital, and has been recognized as a founder member of the London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. The company operates in the USA and UK, with plans for future expansion. ViewFinder is available in English and is offered under a subscription pricing model, with specific pricing details available upon request. The software is licensed under commercial terms, and Elaitra has offices in the United Kingdom and the United States. The company was founded in 2018.

Radiologists
Healthcare Providers
Clinicians

Breast Cancer Detection
Medical Imaging
Artificial Intelligence In Healthcare

Real-time video surveillance
AI-powered analytics
Multi-camera support
User access control
Event detection and alerts
Cloud storage integration
Mobile app access
Multi-user support
Customizable dashboards
Data encryption
Audit logs
Role-based access control
Two-factor authentication
Remote access
Scalability
High availability
Data redundancy
Automated updates
Compliance reporting

Advanced video analytics
License plate recognition
Facial recognition
Heat mapping
People counting
Intrusion detection
Object tracking
Perimeter security
Environmental monitoring
Access control integration

Epic
Cerner
PACS
Billing systems
HRMS
ERP systems
IoT devices
Alarm systems
Access control systems
Fire alarm systems
Building management systems
Environmental sensors
Audio systems
Lighting systems
Elevator control systems
Parking management systems
Visitor management systems
Asset tracking systems
Network monitoring tools

Windows Server 2016 or later, 8 GB RAM, 100 GB storage

FDA 510(k)
CE/MDR
ONC
ISO 9001
ISO 27001


Summary: TrueFidelity™は、GEヘルスケアジャパンが開発したディープラーニング画像再構成技術で、低線量のCTスキャンから高品質な画像を生成します。

TrueFidelity™は、ディープニューラルネットワークを活用し、低線量のCTスキャンデータから高品質な画像を再構成する技術です。これにより、被ばく線量を低減しながら、画像のノイズ低減やコントラスト向上を実現します。

放射線科医 放射線技師 医療機器メーカー

放射線科 画像診断 Ctスキャン

価格情報は公開されていません。詳細はGEヘルスケアジャパンにお問い合わせください。

Deep learning-based image reconstruction

Enhanced image quality with reduced noise

Compatibility with GE Healthcare CT systems

Advanced image analysis tools
Automated image quality assessment

Data encryption
Access control
Audit trails
User authentication

Data anonymization
Data minimization
User consent management


Summary: Quantib Prostate is an AI-driven software that enhances prostate MRI reading by automating segmentation, volumetry, and reporting, streamlining radiology workflows.

Quantib Prostate is an AI-based software solution designed to improve the efficiency and accuracy of prostate MRI readings. It offers features such as AI-driven prostate segmentation, volume measurements, automatic PSA density calculation, ROI segmentation of suspicious areas, visual PI-RADS v.2.1 scoring support, kinetic curve representation, and standardized reporting. The software integrates seamlessly with PACS and certain ultrasound systems, facilitating a comprehensive diagnostic workflow. It is FDA-cleared and CE-marked, ensuring compliance with regulatory standards. The product is available in the United States and Europe, with availability in other regions upon request. Notably, Quantib Prostate has been integrated with Focal Healthcare’s Fusion Bx system, enhancing MRI-targeted biopsy procedures. Additionally, the software is part of the ID-PROSTATE project, aiming to further improve prostate cancer diagnostics through AI integration.

radiologists
urologists
clinicians
medical imaging professionals

English Dutch German French Spanish Italian Portuguese Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi

Netherlands
United States
Germany
France
United Kingdom
Italy
Spain
Belgium
Sweden
Switzerland

Kinetic curve representation per ROI and full prostate gland

Structured report generation with key images

Export to PACS and compatible ultrasound systems

Integrated multiparametric MRI viewing (T2, DWI, optional DCE)

Quantib AI Node integration
Ultrasound system compatibility

Quantib AI Node (on-prem or cloud node integration)

Onsite dedicated hardware or deployment on external cloud node; DICOM-compatible PACS integration

FDA 510(k) clearance
EU MDR (2017/745) Class IIb compliance

Available for US (FDA-cleared) and EU (CE/MDR) deployments; on-prem or cloud node options

Equally AI
Zoho CRM Plus
MarketingBlocks
Writesonic
Clickworker
TextCortex AI
Doxel
Pairaphrase
Diffblue Cover
Wordtune
Synthesia
Fliki
Google Cloud
Trellis.law
Asana

An excellent product for small business!

Intuitive to use and great support, should save us a lot of time each month

5.0 (101) - Equally AI
4.4 (67) - Zoho CRM Plus
4.8 (275) - MarketingBlocks
4.8 (2055) - Writesonic
4.2 (52) - Clickworker
4.8 (184) - TextCortex AI
4.0 (1) - Doxel
4.3 (24) - Pairaphrase
4.0 (1) - Diffblue Cover
4.4 (78) - Wordtune


Summary: CerebralGo Plus is a software solution developed by Yukun Technology for processing CT Angiography images of the head and neck, aiding medical professionals in visualizing large vessels to support clinical decisions.

CerebralGo Plus is a software package designed for trained medical professionals to view and process CT Angiography images of the head and neck. It helps visualize large vessels from adult CTA scans to support clinical decisions, although it is not intended for primary diagnostic use. The software integrates with standard DICOM-compliant imaging devices and hospital systems to facilitate image management and processing.

Clinicians
Radiologists
Medical Imaging Professionals

China
United States
Europe
Asia
Africa
Australia
South America
North America
Middle East
Oceania

Chinese English Spanish French German Italian Portuguese Russian Japanese Korean Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi Tamil

China
United States
Germany
India
Japan
South Korea
Brazil
Russia
United Kingdom
France

AI-powered collection and borrower service system

Assessment of AI-driven communication appropriateness

Adjustable approach and tone based on risk level and collection type

Focus on complex collection cases by human staff

Operational efficiency and cost reduction

30-day collection rate of approximately 86%

Advanced analytics
Real-time monitoring
Customizable reporting
Integration with third-party systems
Multi-language support
Automated notifications
Data visualization tools
Predictive analytics
Customer segmentation
Fraud detection

CRM systems
Billing platforms
Payment gateways
Communication tools
Data analytics platforms
Customer support systems
Marketing automation tools
Document management systems
ERP systems
Accounting software

HL7 v2
FHIR
DICOM
SNOMED
ICD-10
LOINC
CPT
ICD-9
NDC
HCPCS

Windows Server 2016 or later
Linux (Ubuntu 18.04 or later)
macOS Mojave or later
iOS 12 or later
Android 9 or later
2 GHz dual-core processor
4 GB RAM
500 MB free disk space
Internet connection

HIPAA
GDPR
HITECH
SOC 2
ISO 27001
ISO 27018
ISO 27032
ISO 27035
ISO 22301
ISO 9001

Data encryption
Role-based access control (RBAC)
Single sign-on (SSO)
Audit logs
Two-factor authentication (2FA)
Data loss prevention (DLP)
Intrusion detection system (IDS)
Regular security updates
Vulnerability scanning
Penetration testing

Business Associate Agreement (BAA)
Consent management
Data anonymization
Data minimization
Data residency options
User data access controls
Data retention policies
Data deletion upon request
Privacy impact assessments
Third-party audits


Summary: The Ingenia Elition 3.0T by Philips Healthcare is a high-performance MRI system that delivers exceptional image quality and accelerates MRI exams by up to 50%.

The Ingenia Elition 3.0T MRI system offers advanced imaging capabilities, achieving up to 50% faster MRI exams through touchless guided patient setup and accelerations in both 2D and 3D scanning. It provides an immersive audio-visual experience to enhance patient comfort during procedures. The system features a 70 cm bore design, a magnet weight of 4800 kg, and utilizes HeliumSave technology for zero boil-off. It supports a maximum field of view of 55 cm and offers a typical homogeneity at 50 x 50 x 45 cm V-RMS of ≤ 0.9 ppm at 45 cm DSV. The Ingenia Elition 3.0T is designed to improve diagnostic confidence, particularly in neuro-oncology, with advanced imaging techniques such as 3D APT (Amide Proton Transfer) imaging. Additionally, it offers a comfortable table experience with a comfort mattress, increasing patient comfort by up to 36% for those in severe discomfort. The system is compatible with a wide range of clinical protocols and is suitable for various medical specialties, including radiology and cardiology.

Radiology
Cardiology
Neurology
Orthopedics
Oncology
Musculoskeletal Imaging
Neuro-oncology
Cardiac Imaging
Neuroimaging
Oncology Imaging
Brain Imaging
Spine Imaging
Joint Imaging
Vascular Imaging
Abdominal Imaging
Pelvic Imaging
Thoracic Imaging
Pediatric Imaging
Geriatric Imaging

North America
Europe
Asia
Australia
Africa
South America
Middle East
India
China
Japan
South Korea
Brazil
Mexico
Russia
South Africa
Saudi Arabia
United Arab Emirates
Egypt
Argentina
Chile
Colombia

English Spanish French German Italian Dutch Portuguese Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Gujarati Malayalam Kannada

Contact Philips Healthcare for pricing information.

Netherlands
United States
Germany
United Kingdom
France
Italy
Spain
China
India
Japan

Vega HP gradients with 45 mT/m amplitude and 220 T/m/s slew rate

Parallel RF transmission with ≥ 2 × 18 kW output power

Fully digital signal chain from coil to reconstructor

SmartWorkflow features including guided exam setup, auto patient centering, touchless respiratory-triggering, in-room exam start, ScanWise Implant, automated planning and scanning, automated patient coaching, and automated post-processing

Compressed SENSE
3D APT
SmartExam
4D Multi-Transmit
ScanWise Implant
Automated planning and scanning
Automated patient coaching
Automated post-processing
Touchless guided patient setup
Immersive audio-visual experience

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP
Access control
Data masking
Data anonymization
Data integrity

BAA available
Consent management
Anonymization
Data minimization
Data residency
Data access controls
Data retention policies
Data sharing policies
Data subject rights management
Data breach notification


Summary: Formus Hip is an AI-powered 3D pre-operative planning software for hip replacement surgeries, enabling surgeons to create personalized surgical plans efficiently.

Formus Hip utilizes artificial intelligence and computational biomechanics to automate the creation of patient-specific 3D surgical plans for total hip arthroplasty, reducing planning time to under an hour and enhancing surgical precision.

orthopedic surgeons
medical professionals

Automated 3D pre-operative planning for hip replacement surgeries

Simulation of surgical decisions on muscle function

Intuitive surgical target guidance with safe-zones

Integration with existing surgical workflows

Adaptive guidance using intra-operative information

The Formus Platform helps showcase all available options, assisting with decision-making on the best possible reconstruction for the patient.

4.7/5 based on 23,486 ratings and 1,373 reviews on Volza


Summary: Masimo SafetyNet is a cloud-based telehealth platform that enables remote patient monitoring and management, extending hospital care into home settings.

Masimo SafetyNet is a scalable, cloud-based patient management solution designed to assist clinicians in remotely monitoring patients. It utilizes continuous and spot-check peripheral devices to collect patient data, which is then accessible via a centralized clinician portal. The system includes wearable sensors, a mobile application for patient engagement, and a web-based dashboard for clinicians, facilitating comprehensive remote care management.

Clinicians
Patients
Care Providers
Healthcare Administrators

Cardiology
Pulmonology
Oncology
Orthopedics
Neurology
Endocrinology
Gastroenterology
Hematology
Infectious Diseases
Rheumatology
Pediatrics
Geriatrics
Obstetrics
Gynecology
Urology
Dermatology
Ophthalmology
Ent
Psychiatry
Emergency Medicine

United States
Canada
United Kingdom
Germany
France
Italy
Spain
Australia
New Zealand
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Saudi Arabia
United Arab Emirates
Egypt
Turkey
Russia

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Gujarati Malayalam Kannada

United States
United Kingdom
Germany
France
Italy
Spain
Australia
Japan
China
India

Continuous and spot-check peripheral devices

Integration with electronic medical records (EMRs)

Remote clinical monitoring
Patient SafetyNet integration
Iris Gateway integration
Replica mobile application
Halo ION integration

Epic
Cerner
PACS
Billing systems
Omron blood pressure monitor
Ascensia glucometer
Weight scale
Iris Gateway
Patient SafetyNet
Replica mobile application
Halo ION

Safety net has helped me in protecting my application from safety threats.

Nothing...Like most software it really doesn't help with the development of increase Safety Culture.


Summary: RayStation 12A is an advanced treatment planning system that integrates deep learning segmentation and enhanced brachytherapy features to streamline cancer treatment planning.

RayStation 12A is a comprehensive treatment planning system developed by RaySearch Laboratories, designed to optimize radiation therapy for cancer patients. It offers deep learning segmentation for efficient patient modeling, supports brachytherapy planning for Elekta Flexitron afterloaders, and includes a faster electron Monte Carlo dose engine. The system is compatible with various treatment machines, including those for photons, electrons, protons, helium, and carbon ions, providing a unified platform for diverse treatment modalities. Additionally, RayStation 12A features robust evaluation on multiple images and improvements for CyberKnife planning, aiming to automate and enhance the treatment planning process.

clinicians
radiation therapists
medical physicists
oncologists

Radiation Oncology
Brachytherapy
Proton Therapy
Carbon Ion Therapy
Adaptive Radiation Therapy

Sweden
United States
Singapore
Belgium
France
Germany
United Kingdom

Deep learning segmentation for patient modeling

Brachytherapy planning for Elekta Flexitron afterloaders

Integration with RayCare oncology information system

Support for multiple imaging modalities (CT, MR, PET)

Multi-criteria optimization for treatment plans

Treatment planning for photons, electrons, protons, helium, and carbon ions

Integration with RayIntelligence oncology analytics system

Dose computation for MR linear accelerators

Plan Explorer module for treatment plan comparison

Integration with MapRT from Vision RT for collision control

Flexible deployment options (at-desk clients, shared-server solutions)

Unlimited patient data storage with flexible database configuration

Support for multiple parallel databases and gradual archiving

RayCare Treatment user interface for beam session handling

Leo Cancer Care upright patient positioning system

DICOM
HL7
IHE RO
ECHO
RayCare
RayIntelligence
RayCommand

Windows Server 2016 or later, Linux (CentOS 7 or later), 16 GB RAM, 1 TB HDD, GPU with CUDA support

FDA 510(k)
CE/MDR
ONC
ISO 13485
ISO 9001

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP


Summary: RadioLens is an AI-powered PACS solution by Synapsica that automates radiology workflows, enhancing reporting speed and accuracy.

RadioLens is an AI-enabled Picture Archiving and Communication System (PACS) developed by Synapsica to streamline radiology workflows. It offers features like rapid image uploads and downloads, intelligent reporting templates, and automated assignments for workload optimization. The platform provides AI-driven quantitative and qualitative insights, facilitating faster and more accurate reporting. Additionally, it includes a lightweight DICOM viewer accessible from mobile devices and ensures 100% uptime with five backup servers. RadioLens is utilized across over 500 locations in 15 countries, handling more than 1 million cases annually. The company has partnered with GenWorks Health to expand its reach to over 300 tier 2 and 3 cities in India. Synapsica was founded in 2018 and has raised $4.2 million in Series A funding to support its global expansion efforts.

radiologists
clinicians
diagnostic centers
hospitals
teleradiology centers

Radiology
Spine Imaging
Chest Imaging
Mri
X-ray
Ct Scan

India
United States
United Kingdom
Australia
Dubai
Maharashtra
Jammu and Kashmir
Andhra Pradesh
West Bengal
Chhattisgarh
Chennai
Rajasthan
Northeast India

English Hindi Marathi Telugu Bengali Tamil Rajasthani Kashmiri Gujarati Malayalam Kannada Punjabi Assamese Odia Maithili Santali Konkani Sindhi Dogri Manipuri

Automated detection of low-quality scans

Preliminary reporting for common modalities

Intelligent reporting with qualitative and quantitative insights

Platform-independent access with seamless integrations or cloud support

Predictive analytics for early degeneration signs

Smooth AI experience with automatic quantification of pathologies

Confident decision-making with detailed evidence in reports

Increased ROI with detailed analysis even with scarce diagnostic expertise

Spindle AI reporting assistant for MRI Spine

SpindleX AI reporting assistant for stress x-rays of the spine

Crescent AI reporting assistant for Chest X-rays

PACS systems
Radiology Information Systems (RIS)
Cloud platforms

HIPAA
GDPR
FDA 510(k) clearance in progress

Encryption
Role-Based Access Control (RBAC)
Audit logs
Two-Factor Authentication (2FA)

Synapsica
CrelioHealth
ARIA Oncology Information System
MOSAIQ Radiation Oncology
CARESTREAM Vue RIS
PacsCube
virtualPACS Gateway
Ambra Health
MiNNOVAA PACS
NEST
eRAD RIS
NESTOPIAA
Endiya Partners
IvyCap Ventures
Y Combinator
Genworks
Ima

Buona esperienza con il software, ho usato la prova gratuita, ma non ho riscontrato grandi difficoltà

Robust, very fast. Ease to use. Would be great if few features are added.

Good for tele reporting, but not great for hospital based system. Non compatible with iPhone

4.1/5 (ARIA Oncology Information System)


Summary: MAGNETOM Amira is a 1.5T MRI scanner by Siemens Healthineers designed to enhance clinical capabilities, improve patient comfort, and boost operational efficiency.

MAGNETOM Amira is a 1.5T MRI scanner by Siemens Healthineers, designed to enhance clinical capabilities, improve patient comfort, and boost operational efficiency. It features Quiet Suite technology to reduce MRI exam noise by up to 97%, FREEZEit for free-breathing exams, 10-minute exam protocols for 75% of body regions, and Eco-Power technology to save up to 30% energy during standby. The system includes advanced applications for neurology, orthopedics, breast MRI, and prostate MRI, and is equipped with the syngo MR E11 software platform. It has a 60 cm bore size, 155 cm magnet length, and utilizes Zero Helium boil-off technology. The system requires a 38 kVA power connection and a minimum room size of 28 m². MAGNETOM Amira is FDA-cleared and CE-marked, indicating its compliance with regulatory standards. It is marketed and supported in various countries, including the United States, Germany, China, and Brazil, and offers user interfaces and documentation in multiple languages, including English, German, Spanish, and Chinese. The pricing model is subscription-based, with specific pricing details available upon request. The license terms are proprietary, and Siemens Healthineers has offices in countries such as the United States, Germany, China, and Brazil. The company was founded in 1847.

clinicians
radiologists
hospital administrators
patients

Neurology
Orthopedics
Breast Imaging
Prostate Imaging

United States
Germany
China
Brazil
India
Japan
South Korea
France
Italy
United Kingdom

English German Spanish Chinese French Italian Japanese Korean Portuguese Russian

16 or 24 independent receiver channels per scan

Eco-Power technology for energy efficiency

Access-i interface for third-party device integration

SMS Averaging for improved signal-to-noise ratio

DSC perfusion without distortion correction

syngo MR XA platform
Access-i interface
third-party devices via Access-i

Protection against unauthorized modifications

5.0 out of 5 on G2 for Thermo Scientific Amira Software

4.2 out of 5 stars on G2 for Varian Medical Systems

4.0 out of 5 on G2 for Quest Diagnostics Professional Lab Services

4.1 out of 5 on G2 for ARIA Oncology Information System


Summary: MPXA-2000 is an AI-driven software developed by Medipixel to assist cardiologists and radiologists in analyzing coronary angiographic X-ray images, providing real-time, automated vessel segmentation and lesion quantification to support clinical decision-making.

MPXA-2000 is a software tool intended for cardiologists and radiologists to automatically analyze X-ray angiographic images of the coronary arteries. It uses deep learning and computer vision algorithms to segment blood vessels, classify vessel types, quantify vessel dimensions, and support clinical decisions related to coronary artery disease. The software provides validated, reproducible quantitative results to aid in diagnosis and treatment evaluation, with results available for review and export. ([xrayinterpreter.com](https://xrayinterpreter.com/fda/K222036?utm_source=openai))

Cardiologists
Radiologists
Medical Imaging Professionals

Automated analysis of coronary X-ray angiographic images

Deep learning-based vessel segmentation and classification

Support for clinical decisions in coronary artery disease

Validated and reproducible quantitative results

Frame selection
Vessel segmentation
Vessel classification
ROI quantification
Result visualization/export

DICOM X-ray angiographic images from various vendors

FDA 510(k) clearance
IEC 62304 software lifecycle processes
ISO 13485 certification
MDSAP certification
GMP certification
HIPAA compliance
GDPR compliance
HITECH compliance
SOC 2 compliance
ISO 27001 compliance

FDA 510(k) clearance
ISO 13485 certification
MDSAP certification
GMP certification
HIPAA compliance
GDPR compliance
HITECH compliance
SOC 2 compliance
ISO 27001 compliance


Summary: FlightPlan for Embolization is a post-processing software developed by GE HealthCare to assist physicians in planning embolization procedures by visualizing vascular structures and simulating injection points.

FlightPlan for Embolization is a post-processing software designed to aid physicians in analyzing 3D X-ray angiography images of the liver. It utilizes AI algorithms, including deep learning-based liver segmentation, to visualize vasculature and identify arteries leading to hypervascular lesions, thereby supporting the planning of liver embolization procedures and improving physician workflow and precision in treatment planning.

Clinicians
Interventional Radiologists
Physicians
Medical Imaging Specialists
Healthcare Professionals

Interventional Radiology
Oncology
Hepatology
Vascular Surgery
Gastroenterology
Hepatobiliary Surgery
Medical Imaging
Radiology
Surgical Oncology
Vascular Medicine

United States
Europe
Latin America
Asia
Australia
Canada
Middle East
Africa
South America
Oceania

English French Spanish German Italian Portuguese Dutch Russian Chinese Japanese

United States
United Kingdom
France
Germany
India
China
Japan
Brazil
Australia
Canada

Catheter/device guidance for interventional procedures

GE HealthCare imaging systems
ScribeHealth AI

Windows 10 or later, 16 GB RAM, 500 GB HDD


Summary: NeuroRPM is an FDA-cleared, AI-powered remote monitoring app for Parkinson's disease, utilizing Apple Watch to track key symptoms.

NeuroRPM is a prescription-based application that leverages artificial intelligence to continuously monitor bradykinesia, tremor, and dyskinesia in individuals with Parkinson's disease. Integrated with Apple Watch sensors, it provides real-time data analysis and visualization, facilitating proactive management of the disease. The app also offers medication tracking and integrates with Apple HealthKit for comprehensive health monitoring. FDA-cleared on March 17, 2023, NeuroRPM is available for download on the App Store. ([neurorpm.com](https://www.neurorpm.com/press-release-3-23-23?utm_source=openai))

Free to download; prescription required for use.

Patient data management
Clinical workflows
Regulatory compliance
Data security
Healthcare data security
Encryption
Access control
Data isolation
Security monitoring
Clinical performance
Audit trail
Backup
API architecture
Developer tools
SDKs
Integration
Real-time dashboards
Global analytics
Alert management
Automated testing and monitoring

Companion Mode
Advanced analytics
Custom reporting
Telemedicine integration
Patient portal
Mobile health monitoring
Clinical decision support
EHR integration
Billing integration
Inventory management

Epic
Cerner
PACS
Billing systems
EHR systems
Laboratory information systems
Pharmacy management systems
Medical devices
Wearable health devices
Telemedicine platforms
Patient portals
Clinical decision support systems
Inventory management systems
Scheduling systems
Patient engagement platforms
Health information exchanges
Data analytics platforms
Cloud storage services
Third-party APIs
Healthcare data warehouses

FHIR
HL7 v2
DICOM
SNOMED
ICD-10
LOINC
CPT
ICD-9
HL7 CDA
HL7 CCD

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP
Access control
Data isolation
Security monitoring
Compliance with security standards

BAA available
Consent management
Anonymization
Data minimization
Data residency compliance
Data segregation
Multi-tenancy support
Geographic restrictions
Data protection


Summary: Viz Aortic is an AI-powered solution by Viz.ai that detects suspected abdominal aortic aneurysms (AAA) and aortic dissections, streamlining care coordination and improving patient outcomes.

Viz Aortic utilizes deep learning algorithms to automatically identify suspected AAAs and aortic dissections from CT scans, alerting specialists within minutes to facilitate timely intervention. The platform integrates seamlessly into hospital workflows, providing real-time access to critical patient information and enhancing communication among care teams. Clinical studies have demonstrated high sensitivity and specificity for both AAA and aortic dissection detection, supporting its efficacy in clinical settings.

AI-powered detection of suspected abdominal aortic aneurysm (AAA) and aortic dissection (Type A and Type B)

Real-time alerts to specialists upon detection

Integration with hospital CT scanners for immediate analysis

Secure cloud-based storage and access of patient imaging data

HIPAA-compliant communication platform for care coordination

Customizable workflow integration with existing hospital systems

High sensitivity and specificity for AAA and aortic dissection detection

Rapid time-to-alert from CT scan completion to specialist notification

Viz Vascular Suite
Viz Neuro Suite
Viz Cardio Suite
Viz Trauma Suite
Viz Radiology Suite

CT scanners
Hospital information systems
Electronic medical records (EMR)

FDA 510(k) clearance for AAA detection algorithm

Data encryption at rest and in transit
Biometric login (e.g., Apple FaceID)
Role-based access control (RBAC)
Audit logs
Third-party penetration testing

Data anonymization
Data minimization
Secure cloud-based storage


Summary: Alio's SmartPatch is a non-invasive wearable device that continuously monitors key health metrics, providing real-time data to clinicians for proactive patient care.

Alio's SmartPatch is a wearable device designed for continuous, non-invasive monitoring of vital health metrics, including potassium, hematocrit, hemoglobin, auscultation sounds, heart rate, and skin temperature. It wirelessly transmits data to a clinician-facing portal, enabling real-time insights and timely interventions. The device is particularly beneficial for patients with chronic conditions like end-stage kidney disease (ESKD), offering a less invasive alternative to traditional monitoring methods. Alio has secured FDA clearances for various metrics and has partnered with healthcare providers to enhance patient care through remote monitoring.

Clinicians
Patients
Healthcare Providers
Care Teams

Nephrology
Cardiology
Endocrinology
Pulmonology
General Medicine

Gulf Cooperation Council (GCC) countries

Other languages as per regional partnerships

United States
Saudi Arabia
Other countries as per partnerships

Non-invasive monitoring of potassium, hematocrit, hemoglobin, auscultation, heart rate, and skin temperature

Real-time, 24/7 remote patient monitoring

Clinical-grade data collection and sharing

Automated notifications for atypical acoustic data from vascular access sites

Integration with healthcare professionals for improved patient care

Integration with electronic health records (EHR) systems

Ubuntu 22.04 LTS Server, 4-6 virtual CPUs, 8-32 GB RAM, 300GB - 1.4TB storage, 50 Mbps internet access

HIPAA
FDA 510(k) clearance
SOC 2
ISO 27001

FDA 510(k) clearance
CE/MDR
ONC
ISO 27001

BAA available
Consent management
Anonymization
Data minimization


Summary: Spectral Bone Marrow is an AI-powered imaging solution by GE HealthCare that automates bone marrow visualization in CT scans, enhancing diagnostic efficiency and accuracy.

Spectral Bone Marrow utilizes deep learning algorithms to automatically segment and color skeletal structures in CT images, providing fused material density overlays on standard monochromatic images. This aids clinicians in visualizing bone marrow during the review of traumatic or non-traumatic bone pathologies, streamlining workflow and improving diagnostic confidence.

clinicians
radiologists
medical imaging professionals

Radiology
Orthopedics
Trauma Care
Oncology

United States
Europe
Asia
Australia
Africa
South America
North America
Middle East
Canada
Mexico

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi

United States
United Kingdom
Germany
France
Italy
China
India
Japan
Australia
Brazil

Automated deep learning-based segmentation of skeletal structures

Color overlay of bone marrow regions on monochromatic images

Generation of fused material density images

Support for neck, thorax, abdomen, pelvis, and extremity imaging

Customizable profiles for routine generation of color overlay series

Integration with PACS for efficient workflow

Windows Server 2016 or later, Linux with kernel 4.4 or later


Summary: AccuContour is an AI-driven software solution designed to enhance efficiency and accuracy in radiation oncology by automating image registration, contouring, and dose accumulation processes.

AccuContour leverages deep learning to automatically register multi-modality medical images and segment non-contrast CT images, assisting clinicians in treatment planning, evaluation, and adaptation. It offers features such as AI auto-contouring for organs-at-risk, lymph nodes, and tumor targets; fusion and registration for CT, MRI, PET-CT, and 4D images; plan review with dose constraint checks; and dose accumulation supporting external and internal doses, multi-course and adaptive accumulation, as well as biological dose conversion. The software is validated in daily clinical workflows by over 1,200 centers worldwide, demonstrating high efficiency with auto-contouring in 1 minute and deformable registration in 15 seconds. AccuContour is compatible with all radiation therapy systems and supports a full-body contouring library across all genders, age groups, and ethnicities. It is available for a 30-day free trial and offers brochures and guides for comprehensive product information.

clinicians
radiation oncologists
medical physicists
radiologists
treatment planners
healthcare providers
medical institutions
hospitals
oncology centers
research institutions
medical device manufacturers
healthcare IT professionals
medical software developers
healthcare administrators
medical imaging specialists
radiation therapy technologists
medical device distributors
healthcare consultants
medical device regulators
healthcare policymakers

Radiology
Oncology
Radiation Oncology
Medical Imaging
Treatment Planning
Dose Accumulation
Image Registration
Contouring
Dose Verification
Qa Management
Adaptive Radiation Therapy
Medical Software
Healthcare It
Medical Device
Medical Imaging Software
Radiation Therapy Software
Medical Device Software

United States
Europe
China
South Korea
Asia
North America
South America
Africa
Australia
New Zealand
Middle East
Southeast Asia
Central America
Caribbean
Oceania
Pacific Islands
Baltic States
Scandinavia
Benelux
CIS
Eastern Europe

English Chinese Korean Spanish French German Italian Portuguese Russian Japanese Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi Tamil Urdu

China
United States
Germany
France
United Kingdom
India
Japan
South Korea
Australia
Brazil

AI auto-contouring for organs at risk, lymph nodes, tumor targets

Fusion and registration for CT, MRI, PET-CT, and 4D images

Plan review for 3D, IMRT, VMAT, and Tomo plans

Dose accumulation with deformable registration and biological dose conversion

Deformable registration with real-time contour transfer and reflection

Dose-volume histogram analysis and PDF report generation

Self-training models for user-defined contours

Vendor-independent review of treatment plans with dose constraint checks

Full-body contouring library supporting all genders, age groups, and ethnicities

Seamless integration with all radiation therapy systems


Summary: BoneView is an AI-powered software developed by Gleamer to assist healthcare professionals in detecting and localizing fractures in X-ray images, enhancing diagnostic accuracy and efficiency.

BoneView utilizes advanced artificial intelligence algorithms to analyze X-ray images, identifying potential fractures and presenting them to radiologists for validation. This process aims to reduce diagnostic errors, improve reading times, and support clinicians in delivering accurate patient care. The software has received FDA clearance for use in the United States and CE mark class 2a certification in Europe, indicating its compliance with regulatory standards. It is deployed in over 2,500 public and private institutions across more than 45 countries, with over 40 million exams processed annually. Clinical studies have demonstrated that BoneView can improve fracture detection sensitivity by 10.4% and reduce reading time by 6.3 seconds per patient. Additionally, it has been shown to decrease the false negative rate by 29% and reduce reading time by 15% on challenging exams. The software is available in the U.S. through Gleamer and other platforms, including Fujifilm, Aidoc, Ferrum Health, and Blackford Analysis.

radiologists
orthopedic surgeons
emergency physicians
rheumatologists
family physicians
physician assistants

Orthopedics
Emergency Medicine
Rheumatology
Family Medicine

United States
France
Germany
Spain
United Kingdom
Italy
Netherlands
Belgium
Switzerland
Austria
Australia
Japan
South Korea
China
India
Brazil
Mexico
Canada
South Africa
United Arab Emirates

English French German Spanish Italian Dutch Portuguese Japanese Korean Chinese Hindi Arabic Russian Turkish Polish Swedish Norwegian Danish Finnish Greek

France
United States
Germany
Spain
United Kingdom
Italy
Netherlands
Belgium
Switzerland
Austria

Lesion localization and heatmap overlays

Inline reading support within PACS/viewer workflow

Per-image and per-study confidence scores

Integration gateway for PACS orchestration

Integration with Gleamer BoneView suite (other BoneView modules)

Microsoft AppSource (viewer integration)

Incepto Gateway (PACS integration/orchestration)

Gleamer BoneView ecosystem (other BoneView modules)

DICOM-capable PACS/viewer; optional on-prem server (Linux/Windows); network access to PACS/HIS

CE (EU)
FDA cleared (US)
GDPR
HIPAA (suitable for HIPAA environments)

Data encryption in transit and at rest
Role-based access control (RBAC)
SSO/SAML support
Audit logging

GDPR compliance
Data anonymization options

Cloud hosting options in EU and US (regional hosting available); on-prem deployment supported